Literature DB >> 9336775

The application of the macular photocoagulation study eligibility criteria for laser treatment in age-related macular degeneration.

Y A Gelfand1, S Linn, B Miller.   

Abstract

BACKGROUND AND
OBJECTIVE: To analyze the application of the Macular Photocoagulation Study eligibility criteria for laser photocoagulation of choroidal neovascularization, in view of the expansion of these criteria in recent years. PATIENTS AND METHODS: The authors prospectively analyzed 50 eyes of 47 consecutive patients with exudative age-related macular degeneration (AMD) to determine their suitability for treatment.
RESULTS: Fifteen eyes (30%) were found to be suitable for laser photocoagulation. Patients eligible for treatment were more likely to have experienced visual symptoms for a months or less (P = .006), to have a visual acuity of 20/200 or better (P = .009), and to be younger in age (P = .02). Visual symptoms experienced for a month or less were more prevalent in extrafoveal exudative lesions compared with the subfoveal type (P = .01)
CONCLUSIONS: Despite recent advances, laser photocoagulation still can be applied only to a minority of the patients with neovascular AMD. Prompt ocular examination following the onset of visual symptoms is essential.

Entities:  

Mesh:

Year:  1997        PMID: 9336775

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers        ISSN: 1082-3069


  4 in total

1.  Yellow dye laser thermotherapy of choroidal neovascularisation in age related macular degeneration.

Authors:  M R Beintema; J A Oosterhuis; F Hendrikse
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

2.  Improved visualisation of choroidal neovascularisation by scanning laser ophthalmoscope using image averaging.

Authors:  D U Bartsch; M H El-Bradey; A El-Musharaf; W R Freeman
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

3.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

4.  Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration.

Authors:  W M Haddad; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.